{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:02:12Z","timestamp":1792627332925,"version":"4.5.0"},"reference-count":93,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Since their first application in psychiatry seventy years ago, antipsychotic drugs, besides schizophrenia, have been widely used in the treatment of mood disorders. Such an application of antipsychotics is the subject of this narrative review. Antipsychotic drugs can be arbitrarily classified into three generations. First-generation antipsychotics (FGAs), such as phenothiazines and haloperidol, were mainly applied for the treatment of acute mania, as well as psychotic depression when combined with antidepressants. The second-generation, so-called atypical antipsychotics (SGAs), such as clozapine, risperidone, olanzapine, and quetiapine, have antimanic activity and are also effective for the maintenance treatment of bipolar disorder. Additionally, quetiapine exerts therapeutic action in bipolar depression. Third-generation antipsychotics (TGAs) started with aripiprazole, a partial dopamine D2 receptor agonist, followed by brexpiprazole, lurasidone, cariprazine, and lumateperone. Out of these drugs, aripiprazole and cariprazine have antimanic activity, lurasidone, cariprazine, and lumateperone exert a significant antidepressant effect on bipolar depression, while there is evidence for the efficacy of aripiprazole and lurasidone in the prevention of recurrence in bipolar disorder. Therefore, successive generations of antipsychotic drugs present a diverse spectrum for application in mood disorders. Such a pharmacological overlap in the treatment of schizophrenia and bipolar illness stands in contrast to the dichotomous Kraepelinian division of schizophrenia and mood disorders.<\/jats:p>","DOI":"10.3390\/brainsci13030414","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T02:28:09Z","timestamp":1677551289000},"page":"414","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Application of Antipsychotic Drugs in Mood Disorders"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0577-0381","authenticated-orcid":false,"given":"Janusz K.","family":"Rybakowski","sequence":"first","affiliation":[{"name":"Department of Adult Psychiatry, Poznan University of Medical Sciences, 60-572 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"ref_1","first-page":"112","article-title":"Utilisation en th\u00e9rapeutique psychiatrique d\u2019une ph\u00e9nothiazine d\u2019action centrale elective","volume":"110","author":"Delay","year":"1952","journal-title":"Ann. M\u00e9d.-Psychol."},{"key":"ref_2","first-page":"337","article-title":"Etude et exp\u00e9rimentations cliniques du R 1625 ou halop\u00e9ridol, nouveau neuroleptique et \u201cneurodysleptique\u201d","volume":"59","author":"Divry","year":"1959","journal-title":"Acta Neurol Psychiatr. Belg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","article-title":"Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine on mouse brain","volume":"20","author":"Carlsson","year":"1963","journal-title":"Acta Pharmacol. Toxicol."},{"key":"ref_4","unstructured":"Linde, O.K. (1988). Pharmakopsychiatrie im Wandel der Zeit, Tilia Verlag. Mensch und Medizin."},{"key":"ref_5","unstructured":"Linde, O.K. (1988). Pharmakopsychiatrie im Wandel der Zeit, Tilia Verlag. Mensch und Medizin."},{"key":"ref_6","first-page":"492","article-title":"The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs","volume":"160","year":"1966","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511, 421\u2013427.","DOI":"10.1038\/nature13595"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2019.04.009","article-title":"Neuroprotective effects of the second generation antipsychotics","volume":"208","author":"Chen","year":"2019","journal-title":"Schizophr Res."},{"key":"ref_10","unstructured":"Linde, O.K. (1988). Pharmakopsychiatrie im Wandel der Zeit, Tilia Verlag. Mensch und Medizin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-0447.1977.tb00224.x","article-title":"Agranulocytosis in patients treated with clozapine","volume":"56","author":"Amsler","year":"1977","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the Treatment-Resistant Schizophrenic","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1192\/S0007125000296876","article-title":"The importance of serotonin-dopamine interactions in the action of clozapine","volume":"160","author":"Meltzer","year":"1992","journal-title":"Br. J. Psychiatry Suppl."},{"key":"ref_14","first-page":"108","article-title":"Is clozapine a mood stabilizer?","volume":"56","author":"Zarate","year":"1995","journal-title":"J. Clin. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","article-title":"Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences","volume":"192","author":"Aringhieri","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bdi.12608","article-title":"Meaningful aspects of the term \u2018mood stabilizer\u2019","volume":"20","author":"Rybakowski","year":"2018","journal-title":"Bipolar. Disord."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1017\/S146114570700795X","article-title":"Two generations of mood stabilizers","volume":"10","author":"Rybakowski","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.biopsych.2010.01.015","article-title":"Risperidone long-acting injectable monotherapy in the maintenence treatment of bipolar disorder","volume":"68","author":"Quiroz","year":"2010","journal-title":"Biol. Pychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1744-6163.2002.tb01566.x","article-title":"Biological perspectives. Aripiprazole: A third generation of antipsychotics begins?","volume":"38","author":"Keltner","year":"2002","journal-title":"Perspect Psychiatr. Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/138161210790361461","article-title":"Third generation antipsychotic drugs: Partial agonism or receptor functional selectivity?","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.schres.2018.08.020","article-title":"Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data","volume":"204","author":"Earley","year":"2019","journal-title":"Schizophr. Res."},{"key":"ref_22","unstructured":"Rybakowski, J. (2022). Psychofarmakologia Kliniczna (Clinical Psychopharmacology), Pa\u0144stwowy Zak\u0142ad Wydawnictw Lekarskich."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5694\/j.1326-5377.1949.tb36912.x","article-title":"Lithium salts in the treatment of psychotic excitement","volume":"36","author":"Cade","year":"1949","journal-title":"Med. J. Aust."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5694\/j.1326-5377.1951.tb68249.x","article-title":"The lithium treatment of maniacal psychosis","volume":"2","author":"Noack","year":"1951","journal-title":"Med. J. Aust."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/jnnp.17.4.250","article-title":"The treatment of manic psychoses by the administration of lithium salts","volume":"17","author":"Schou","year":"1954","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/archneurpsyc.1954.02320380093011","article-title":"Chlorpromazine; new inhibiting agent for psychomotor excitement and manic states","volume":"71","author":"Lehmann","year":"1954","journal-title":"AMA Arch. Neurol Psychiatry"},{"key":"ref_27","first-page":"469","article-title":"Chlorpromazine (CLP) et manies; aspects du mode d\u2019action","volume":"82","author":"Favre","year":"1957","journal-title":"Rev. Med. Nancy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/archpsyc.1975.01760280108010","article-title":"Comparison of efficacy of lithium carbonate and chlorpromazine in mania. Report of collaborative study group on treatment of mania in Japan","volume":"32","author":"Takahashi","year":"1975","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_29","first-page":"245","article-title":"ECT versus chlorpromazine in mania","volume":"12","author":"McCabe","year":"1977","journal-title":"Biol. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ho, B.T., and McIsaacs, W.M. (1971). Brain Chemistry and Mental Disease, Plenum Press.","DOI":"10.1007\/978-1-4684-3057-8"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/archpsyc.1975.01760190036004","article-title":"Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol","volume":"32","author":"Shopsin","year":"1975","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis","volume":"378","author":"Cipriani","year":"2011","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/acps.13209","article-title":"How to treat mania","volume":"142","author":"Pacchiarotti","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00004714-198612000-00003","article-title":"The pharmacological treatment of delusional depression: Part II","volume":"6","author":"Spiker","year":"1986","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000119086","article-title":"Pharmacotherapy of delusional depression: Experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol","volume":"29","author":"Wolfersdorf","year":"1994","journal-title":"Neuropsychobiology"},{"key":"ref_36","first-page":"331","article-title":"Clozapine in the treatment of manic states","volume":"15","author":"Strzyzewski","year":"1981","journal-title":"Psychiatr. Pol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpsychires.2020.02.026","article-title":"Clozapine in bipolar disorder: A systematic review and meta-analysis","volume":"125","author":"Delgado","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jad.2020.07.109","article-title":"The concept and management of acute episodes of treatment-resistant bipolar disorder: A systematic review and exploratory meta-analysis of randomized controlled trials","volume":"276","author":"Fornaro","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_39","unstructured":"Jarema, M. (2022). Standardy Leczenia Farmakologicznego Niekt\u00f3rych Zaburze\u0144 Psychicznych, Via Medica."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","article-title":"Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzapine HGGW Study","volume":"57","author":"Tohen","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1089\/cap.2022.0035","article-title":"Psychopharmacological Treatment Algorithms of Manic\/Mixed and Depressed Episodes in Pediatric Bipolar Disorder","volume":"32","author":"Hobbs","year":"2022","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.59.1.62","article-title":"Efficacy of Olanzapine in Combination with Valproate or Lithium in the Treatment of Mania in Patients Partially Nonresponsive to Valproate or Lithium Monotherapy","volume":"59","author":"Tohen","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jad.2015.11.002","article-title":"Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium","volume":"191","author":"Ketter","year":"2016","journal-title":"J. Affect. Disord."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00023210-200519050-00005","article-title":"Risperidone: A review of its use in the treatment of bipolar mania","volume":"19","author":"Fenton","year":"2005","journal-title":"CNS Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","article-title":"Combination of a Mood Stabilizer With Risperidone or Haloperidol for Treatment of Acute Mania: A Double-Blind, Placebo-Controlled Comparison of Efficacy and Safety","volume":"159","author":"Sachs","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/YIC.0b013e32836290d2","article-title":"Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: Meta-analyses of randomized-controlled trials","volume":"28","author":"Vita","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40261-017-0592-2","article-title":"A review of asenapine in the treatment of bipolar disorder","volume":"38","author":"Vieta","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0b013e31823f872f","article-title":"Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: Results of a 12-week core study and 40-week extension","volume":"32","author":"Szegedi","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.jcp.0000169068.34322.70","article-title":"Ziprasidone in acute bipolar mania: A 21-day randomized, double-blind, placebo-controlled replication trial","volume":"25","author":"Potkin","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1034\/j.1399-5618.2003.02258.x","article-title":"Ziprasidone-associated mania: A case series and review of the mechanism","volume":"5","author":"Baldassano","year":"2003","journal-title":"Bipolar Disord."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bdi.12272","article-title":"Clozapine for treatment-resistant bipolar disorder: A systematic review","volume":"17","author":"Li","year":"2014","journal-title":"Bipolar Disord."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1176\/appi.ajp.163.2.247","article-title":"Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients with Bipolar I Disorder Responding to Acute Treatment With Olanzapine","volume":"163","author":"Tohen","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1176\/appi.ajp.162.7.1281","article-title":"Olanzapine Versus Lithium in the Maintenance Treatment of Bipolar Disorder: A 12-Month, Randomized, Double-Blind, Controlled Clinical Trial","volume":"162","author":"Tohen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1192\/bjp.184.4.337","article-title":"Relapse prevention in bipolar disorder: 18-month comparison of olanzapine plus mood stabilizer v. mood stabilizer alone","volume":"184","author":"Tohen","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40263-022-00923-3","article-title":"Olanzapine\/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain","volume":"36","author":"Corrao","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/da.22136","article-title":"Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar i disorder: Analysis of two large randomized, placebo-controlled trials","volume":"30","author":"Suppes","year":"2013","journal-title":"Depress. Anxiety"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jad.2008.01.017","article-title":"Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: A 4-year follow-up naturalistic study","volume":"110","author":"Altamura","year":"2008","journal-title":"J. Affect. Disord."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"818","DOI":"10.4088\/JCP.v62n1011","article-title":"Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: Results from a 6-month, multicenter, open study","volume":"62","author":"Vieta","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jad.2012.01.047","article-title":"A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode","volume":"138","author":"Berwaerts","year":"2012","journal-title":"J. Affect Disord."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2017.16040419","article-title":"Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar i disorder","volume":"175","author":"Szegedi","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/NDT.S9932","article-title":"The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder","volume":"7","author":"Bowden","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4088\/JCP.08m04995gre","article-title":"A Double-Blind, Placebo-Controlled Study of Quetiapine and Lithium Monotherapy in Adults in the Acute Phase of Bipolar Depression (EMBOLDEN I)","volume":"71","author":"Young","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"ref_64","first-page":"45","article-title":"Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression","volume":"280 Pt A","author":"Ciappolino","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1517\/14656566.2011.632368","article-title":"Olanzapine\u2013fluoxetine combination for the treatment of bipolar depression","volume":"12","author":"Citrome","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Szegedi, A., Zhao, J., Van Willigenburg, A., Nations, K.R., Mackle, M., and Panagides, J. (2011). Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: A post hoc analysis of two 3-week clinical trials. BMC Psychiatry, 11.","DOI":"10.1186\/1471-244X-11-101"},{"key":"ref_67","first-page":"8","article-title":"Asenapine in the treatment of bipolar depression","volume":"50","author":"Nuss","year":"2020","journal-title":"Psychopharmacol. Bull."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jad.2008.05.014","article-title":"Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study","volume":"112","author":"Keck","year":"2009","journal-title":"J. Affect. Disord."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4088\/JCP.14m09081","article-title":"Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: A double-blind, placebo-controlled study","volume":"76","author":"Calabrese","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"828088","DOI":"10.3389\/fpsyt.2022.828088","article-title":"Cariprazine Use in Combination With a Mood Stabilizer in First Episode Mania","volume":"13","year":"2022","journal-title":"Front. Psychiatry"},{"key":"ref_71","first-page":"75","article-title":"Management of bipolar I depression: Clinical utility of lurasidone","volume":"11","author":"Findlay","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3084859","DOI":"10.1155\/2017\/3084859","article-title":"Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews","volume":"2017","author":"Fornaro","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2147\/DDDT.S240860","article-title":"Cariprazine as a treatment option for depressive episodes associated with bipolar 1 disorder in adults: An evidence-based review of recent data","volume":"15","author":"Tohen","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","article-title":"Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial","volume":"178","author":"Calabrese","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/YIC.0b013e3283502791","article-title":"Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy","volume":"27","author":"Nelson","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.4088\/JCP.v68n1003","article-title":"Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo","volume":"88","author":"Keck","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1399-5618.2011.00898.x","article-title":"Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: A multicenter, double-blind, randomized study","volume":"13","author":"Marcus","year":"2011","journal-title":"Bipolar Disord."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40345-017-0075-7","article-title":"Long-term use of lurasidone in patients with bipolar disorder: Safety and effectiveness over 2 years of treatment","volume":"5","author":"Pikalov","year":"2017","journal-title":"Int. J. Bipolar Disord."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.euroneuro.2017.06.013","article-title":"Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder","volume":"27","author":"Calabrese","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40345-021-00230-8","article-title":"Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: A 52 week open label study","volume":"9","author":"Higuchi","year":"2021","journal-title":"Int. J. Bipolar. Disord."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41380-021-01334-4","article-title":"Pharmacological treatment for bipolar mania: A systematic review and network meta-analysis of double-blind randomized controlled trials","volume":"2022 27","author":"Kishi","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jad.2020.03.030","article-title":"Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis","volume":"269","author":"Bahji","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1038\/s41380-020-00946-6","article-title":"Mood stabilizers and\/or antipsychotics for bipolar disorder in the maintenance phase: A systematic review and network meta-analysis of randomized controlled trials","volume":"26","author":"Kishi","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40263-019-00629-z","article-title":"Long-Acting Injectable Second-Generation\/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review","volume":"33","author":"Keramatian","year":"2019","journal-title":"CNS Drugs"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Bartoli, F., Callovini, T., Cavaleri, D., Crocamo, C., Riboldi, I., Aguglia, A., De Fazio, P., Martinotti, G., D\u2019Agostino, A., and Ostuzzi, G. (2022). Effect of long-acting injectable antipsychotics on 1-year hospitalization in bipolar disorder: A mirror-image study. Eur. Arch. Psychiatry Clin. Neurosci., Online ahead of print.","DOI":"10.1007\/s00406-022-01522-5"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1176\/ajp.122.5.509","article-title":"The catecholamine hypothesis of affective disorders: A review of the supporting evidence","volume":"122","author":"Schildkraut","year":"1965","journal-title":"Am. J. Psychiatry"},{"key":"ref_87","first-page":"599","article-title":"The current status of research in the catecholamine theories of affective disorders","volume":"1","author":"Bunney","year":"1975","journal-title":"Psychopharmacol. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mp.2017.16","article-title":"The dopamine hypothesis of bipolar affective disorder: The state of the art and implications for treatment","volume":"22","author":"Ashok","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2022.3541","article-title":"A Positron Emission Tomography Study of Dopamine Transporter Density in Patients with Bipolar Disorder With Current Mania and Those With Recently Remitted Mania","volume":"79","author":"Yatham","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":"N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, a a putative mediator of quetiapine\u2019s antidepressant activity","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_91","unstructured":"Kraepelin, E. (1899). Psychiatrie. Ein Lehrbuch f\u00fcr Studierende und \u00c4rzte. 6 Auflage, Barth."},{"key":"ref_92","unstructured":"Bleuler, E. (1911). Dementia Praecox Oder Gruppe der Schizophrenien, Deuticke."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11920-019-1048-6","article-title":"120th Anniversary of the Kraepelinian Dichotomy of Psychiatric Disorders","volume":"21","author":"Rybakowski","year":"2019","journal-title":"Curr. Psychiatry Rep."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/13\/3\/414\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:44:15Z","timestamp":1760121855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/13\/3\/414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":93,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["brainsci13030414"],"URL":"https:\/\/doi.org\/10.3390\/brainsci13030414","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]}}}